Cogent Biosciences
Cogent Biosciences Logo
About Cogent Biosciences
Cogent Biosciences Inc is a biotechnology company focused on developing precision therapies for genetically defined diseases, including cancers, autoimmune conditions, and rare diseases. Its lead product candidate, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor in Phase 3 trials targeting KIT mutations in systemic mastocytosis and gastrointestinal stromal tumors. The company is also developing CGT4859, a selective FGFR2 inhibitor for patients with FGFR mutations. Cogent Biosciences is dedicated to advancing novel therapies to address unmet medical needs.
Address
275 Wyman Street, 3rd Floor
Waltham, 02451
United States
Year founded
2014
Number of employees
200-300
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
